Möchten Sie immer auf dem neuesten Stand bleiben?

- Comprehensive submission includes interim Phase 3 FORTIFY data demonstrating BBP-418’s rapid, consistent treatment effect and favorable safety profile, with statistically significant and clinically...

PHILADELPHIA, March 30, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development...

Dialogue continues with European Medicines Agency (EMA) to advance the development program of oral blarcamesine in early Alzheimer’s disease Additional data submitted to the U.S. FDA with the...

NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced a research and development (R&D) co-funding agreement with Johnson & Johnson for a total of...

– Rademikibart achieved rapid, durable efficacy results across all key endpoints through 52 weeks, with near‑maximal responses achieved in ~90% of patients – – Rademikibart was well tolerated with...

Reaffirms guidance to resubmit the Anaphylm NDA in Q3 2026Received clarifying feedback from the FDA on pharmacokinetic (PK) and human factor (HF) study designsFinal FDA meeting minutes expected by...

TORONTO, March 30, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has arranged a non-brokered private placement...

SHIJIAZHUANG, China, March 30, 2026 (GLOBE NEWSWIRE) -- On March 28 local time, the 22nd International Congress on Luobing Theory was held in Shijiazhuang, Hebei Province. Under the theme of...

Significant improvements in pain, function and patient global outcomes demonstratedLEVI-04 well tolerated and exhibits a favourable safety profile SANDWICH, United Kingdom, March 30, 2026 (GLOBE...

Draupnir’s novel SORTAC platform expands reach of targeted protein degradation to extracellular proteins, demonstrating in vitro and in vivo efficacy against difficult-to-drug targetsStudy further...